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Simple Summary: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia associated 
with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine kinase oncoprotein 
BCR-ABL1. This led to the development of tyrosine kinase inhibitors (TKI), with Imatinib being the 
first TKI approved. Although the vast majority of CML patients respond to Imatinib, resistance to 
this targeted therapy contributes to therapeutic failure and relapse. Here we review the molecular 
mechanisms and other factors (e.g., patient adherence) involved in TKI resistance, the 
methodologies to access these mechanisms, and the possible therapeutic approaches to circumvent 
TKI resistance in CML. 
Abstract: Resistance to targeted therapies is a complex and multifactorial process that culminates in 
the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) 
was the first malignancy recognized to be associated with a genetic alteration, the t(9;22)(q34;q11). 
This translocation originates the BCR-ABL1 fusion gene, encoding the cytoplasmic chimeric BCR-
ABL1 protein that displays an abnormally high tyrosine kinase activity. Although the vast majority 
of patients with CML respond to Imatinib, a tyrosine kinase inhibitor (TKI), resistance might occur 
either de novo or during treatment. In CML, the TKI resistance mechanisms are usually subdivided 
into BCR-ABL1-dependent and independent mechanisms. Furthermore, patients’ 
compliance/adherence to therapy is critical to CML management. Techniques with enhanced 
sensitivity like NGS and dPCR, the use of artificial intelligence (AI) techniques, and the 
development of mathematical modeling and computational prediction methods could reveal the 
underlying mechanisms of drug resistance and facilitate the design of more effective treatment 
strategies for improving drug efficacy in CML patients. Here we review the molecular mechanisms 
and other factors involved in resistance to TKIs in CML and the new methodologies to access these 
mechanisms, and the therapeutic approaches to circumvent TKI resistance. 
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1. Introduction 
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell (HSC) neoplasia 
characterized by an increase in myeloid lineage cells at all differentiation stages [1]. This 
myeloproliferative neoplasm has an incidence of 1–2 cases per 100,000 adults, 
representing approximately 15% of newly diagnosed cases of leukemia in adults [2]. In 
2020, in the United States, it was estimated that about 8450 new CML cases were 
diagnosed, and about 1080 CML patients died. It should be noted that since the 
introduction of Imatinib in 2001, the annual mortality in CML has decreased from 10 to 
20% to 1 to 2%, and the 5-year relative survival between 2011 and 2017 was 70.6% [2,3]. 
With the discovery of the Philadelphia (Ph) chromosome in 1960 [4], CML was the 
first human malignancy to be associated with a consistent chromosomal abnormality [5]. 
This cytogenetic hallmark has origin in the reciprocal translocation between the long arms 
of chromosomes 9 and 22, leading to a smaller chromosome 22, called chromosome 
Philadelphia, that is present in 95% of CML patients [6]. This exchange of genetic material 
establishes the fusion gene BCR-ABL1. This fusion gene emerges from the juxtaposition of 
the proto-oncogene 1 non-receptor tyrosine kinase, ABL1 gene, at chromosome 9 with the 
activator of RhoGEF and GTPase, BCR gene, on chromosome 22 [7]. This oncogene 
encodes the oncoprotein BCR-ABL1, which presents aberrant constitutive tyrosine kinase 
activity being crucial for HSC transformation and leukemia initiation [8]. This activity 
provides survival signals to the malignant cells, inducing cell proliferation and resistance 
to programmed cell death [1]. 
The development of a small molecule with the ability to block the BCR-ABL1 activity 
dramatically changed the disease course, and CML gradually became a chronic disease 
[9,10]. This tyrosine kinase inhibitor (TKI) impairs the interaction of BCR-ABL1 and ATP, 
blocking cell signals and, consequently, reducing cell proliferation and inducing cell death 
f CML clones. Called the “magic bullet” by Time magazine in 2001, Imatinib was the first 
TKI approved by the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) to treat resistant/refractory CML patients [11] and for newly diagnosed 
patients just two years later [5].  
Currently, five TKIs are approved for CML treatment. These TKIs are Imatinib, 
Dasatinib, Nilotinib, Bosutinib, and Ponatinib. Imatinib, Dasatinib, Nilotinib, and 
Bosutinib are the current first-line treatments approved by the FDA and EMA for the 
treatment of CML [2]. The evolution of these drugs to treat CML, over the last two decades, 
has been quite remarkable in a continuous fight against resistance. Radotinib is a second 
generation TKI currently only approved by Korean authorities and Flumatinib was 
approved at the end of 2019 in China for CML treatment. Nonetheless, in spite of the 
massive improvement in CML treatment over the last years with the introduction of TKIs, 
some patients (20–30%) display intrinsic or acquired resistance to treatment during the 
disease course [4,12]. 
Resistance to target therapy is a complex and multifactorial process that culminates 
in the selection of a cancer clone with the ability to evade treatment [13]. In CML, TKIs 
resistance mechanisms are usually subdivided into BCR-ABL1 dependent and 
independent mechanisms [14]. However, in therapeutic guidelines, only BCR-ABL1 
related mechanisms are taken into consideration for dose adjustments or TKI switch [15]. 
The persistence of leukemic stem cells (LSCs) and LSC-like phenotype based on BCR-
ABL1 protein suppression have also been reported as a main TKI resistance mechanisms 
[1]. Furthermore, patient adherence to therapy and the compliance with professional 
instructions are critical in the management of CML [16,17]. 
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The quantification of BCR-ABL1 transcripts and the detection of BCR-ABL1 kinase 
domain (KD) mutations enable timely therapy switches and selection of the most 
appropriate treatments [18]. Although multiple targeted therapies are available for CML 
patients, it is challenging to select the best targeted therapy to each patient. Therefore, the 
use of intelligent techniques (e.g., artificial intelligence (AI)) [19] and the development of 
mathematical modeling and computational prediction methods could anticipate the 
underlying mechanisms of drug resistance and facilitate the design of more effective 
treatment strategies to improve drug efficacy [20]. 
2. Molecular Mechanisms 
Several mechanisms are associated with TKI resistance, including BCR-ABL1 
mutations and overexpression, abnormal activity of drug transporters, activation of 
alternative signaling pathways, DNA repair, and genomic instability, epigenetic 
dysfunction, leukemia stem cell (LSC) persistence, and dysfunction of the immune system 
(Figure 1). 
 
Figure 1. Molecular mechanisms of resistance to TKIs in CML. The molecular mechanisms responsible for TKI resistance 
in CML include: BCR-ABL1 mutations and BCR-ABL1 overexpression; alteration of DNA damage repair and genomic 
instability (increasing the additional chromosome abnormalities (ACAs) and point mutations); changes in drug 
transporters activity (e.g., increased efflux and decreased influx); activation of alternative signaling pathways (e.g., 
PI3K/AKT, JAK/STAT, and RAS/MAPK); changes in leukemia stem-cell metabolism and pathways (e.g., metabolic shift, 
Hypoxia/HIF-1α, and Alox5/β-catenin); epigenetic alterations (e.g., mutations on epigenetic regulating genes such as 
DNMT3A and/or increased methylation of p15 and EBF2 genes); altered expression of microRNAs (e.g., miR-17 and miR-
203); changes in the microenvironment and immunological status (e.g., immunosuppressive bone marrow 
microenvironment (BMM) with increased MDSCs and Treg, plus exhausted T cells). 
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2.1. BCR-ABL1 Mutational Landscape and Overexpression  
The effectiveness of TKI treatment is highly dependent on proper BCR-ABL1–drug 
interaction [21], and the most studied mechanisms are those responsible for the reactiva-
tion of BCR-ABL1 kinase activity [22]. Overexpression of BCR-ABL1 and mutations on the 
fusion gene that impair the binding of TKI to targeted kinase may lead to resistance and 
are classified as BCR-ABL1 dependent mechanisms [23].  
The occurrence of point mutations on the ABL1 KD is the most common TKI re-
sistance mechanism, being more frequent in acquired resistance rather than primary re-
sistance cases and is associated with poor prognosis and higher risk of disease progression 
[13,24,25]. Over 100 different mutations have been identified, affecting more than 50 
amino acids [26]. The mechanism of action of these mutations includes decrease affinity 
of TKI to the binding domain or changes in BCR-ABL1 conformation [27]. The frequency 
of mutations increases with disease progression, occurring in approximately 75% of mye-
loid CML-blast crises (-BC) cases [14]. The mutations’ appearance could result from ge-
netic instability induced by BCR-ABL1, by the selective pressure of pre-existing mutant 
clones, and/or the drug itself, which gradually outgrow the drug-sensitive cells [28,29]. 
The first described BCR-ABL1 mutation was T315I (isoleucine replaces threonine in 
position 315 of BCR-ABL1), a mutation in the TKI binding site. This is the most frequently 
detected mutation among resistant patients (frequency between 4 and 20%) [26,30]. T315I, 
called a "gatekeeper" mutation, confers resistance to all TKI approved to frontline being 
only sensitive to Ponatinib [31]. The location of mutations has different impacts on TKI 
treatment effectiveness, with variable degrees of sensitivity to the different TKIs (Table 1). 
BCR-ABL1 point mutations can be classified into five categories: (I) mutations in the P-
loop (ATP-binding site); (II) mutations that directly affect the binding of TKI (drug contact 
site); (III) mutation in the catalytic domain (C-loop); (IV) mutations on the activation (A)-
loop; (V) mutations in myristate pocket [27,32]. Mutations on the P-loop have been the 
most commonly observed in resistant patients, representing 36 to 48% of cases, alongside 
T351I [33]. These mutations induce destabilization of BCR-ABL1 conformation, impairing 
Imatinib association as well as Nilotinib action. Additionally, patients carrying P-loop 
mutations are related to a higher risk of disease progression [33]. 
Table 1. Most frequent BCR-ABL1 mutation and the sensitivity degree to the approved TKIs. 
BCR-ABL1 Mutation Location $ Imatinib Dasatinib Nilotinib Bosutinib Ponatinib Asciminib 
Wild-type  Sen Sen Sen Sen Sen Sen 
M244 P-loop Sen Sen Sen Sen Sen Sen 
L248 P-loop Int Int Sen Int Sen Sen 
G250 P-loop Res Sen Int Res Sen Sen 
Q252 P-loop Int Int Sen Sen Sen Sen 
Y253 § P-loop Res Sen Res Sen Sen Sen 
E255 § P-loop Res Int Res Int Int Sen 
V299 C-helix Res Res Sen Res Sen Sen 
T315 ‡,§ Drug contact site Res Res Res Res Int Sen 
F317 ‡ Drug contact site Int Res Sen Int Sen Sen 
A337 C-loop Sen Sen Sen Sen Sen Int 
M351 C-loop Sen Sen Sen Sen Sen Sen 
M355 C-loop Int Sen Sen Sen Sen Sen 
F359 § C-loop Int Sen Res Sen Sen Sen 
H396 A-loop Int Sen Int Sen Int Sen 
W464 Myristate pocket Sen Sen Sen Sen Sen Res 
P465 Myristate pocket Sen Sen Sen Sen Sen Res 
V468 Myristate pocket Sen Sen Sen Sen Sen Res 
I502 Myristate pocket Sen Sen Sen Sen Sen Res 
‡ Gatekeeper residue; § Most commonly associated with disease progression and relapse; $ Location of altered amino acid 
on BCR-ABL protein, P-loop: ATP-binding loop; C-loop: catalytic loop; A-loop: activation loop; Sen: sensitive; Int: inter-
mediate sensitivity; Res: resistant. Data derived from the following references: [27,32,34,35]. 
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The knowledge of this resistant mechanism has justified the development of second 
and third-generation TKIs, able to overcome and inhibit mutated BCR-ABL1. However, 
even with these new-generation TKIs, some mutations, such as T315I, remain resistant to 
multiple TKIs [15]. With the approval of second-generation TKIs as frontline CML treat-
ment, fewer mutant clones are expected compared to those emerging under Imatinib treat-
ment since these TKIs can bind even in the presence of some mutations [36]. The majority 
of these BCR-ABL1 mutants are resistant to at least one single-agent TKI, but Eide et al. 
(2019) proposed that combination treatment in particular with Ponatinib and Asciminib 
can be a strategy to overcome this type of resistance [37]. According to the 2017 European 
Society for Medical Oncology (ESMO) management guidelines, BCR-ABL1 mutational 
analysis is recommended for patients who fail Imatinib or second-generation TKIs and 
those who progress to accelerated phase (AP) or BC [38]. However, 30–40% of patients 
with suboptimal responses harbor low-level resistance mutant clones that are detected by 
Sanger sequencing and will be selected unless therapy is changed [39]. In this context, a 
sensitive screening approach should be included in the clinical algorithms for patients 
with suboptimal responses.  
Nevertheless, the presence of one mutation on BCR-ABL1 is not exclusive, as the oc-
currence of other mutations in the same sequence is possible [27]. In some patients, mul-
tiple mutations are identified in different BCR-ABL1 molecules (different CML clones), 
and this is called a polyclonal mutation. However, a current issue in CML treatment is the 
compound mutations which are the presence of two or more mutation occurring in the 
same BCR-ABL1 clone [27]. Although individual mutations could be sensitive to a TKI, 
the interaction between them could lead to resistance [40,41]. One example is the com-
pound mutation T315I/E255V. Each of these mutations, when isolated, are responsive to 
Ponatinib; however, when together, they exhibit increased resistance to this third-gener-
ation TKI [41]. 
The occurrence of mutations outside the kinase domain is less frequent but could 
impact on TKIs resistance. Mutations on the SH domain could affect the BCR-ABL1 con-
formation and consequently compromise the TKI efficacy [42,43]. In addition to point mu-
tations, some studies have reported resistance acquisition by abnormal splicing of BCR-
ABL1. These rare splicing mutations are associated with nucleotides insertion, namely the 
retention of 35 intronic nucleotides on exon 8 to 9 of ABL1 [44,45]. Furthermore, some 
mutations that confer resistance to Asciminib have been identified (Table 1), and available 
preclinical and clinical studies have suggested that mutations in and around the myristy-
lation pocket may also confer resistance to this TKI [32,37,46]. 
BCR-ABL1 expression due to gene amplification or upregulation at the transcrip-
tional level is another resistance mechanism that is only observed in a small proportion of 
patients [30,47]. The overexpression of BCR-ABL1 leads to resistance by increasing the 
oncoprotein concentration needed to be inhibited with TKI. Besides being more probably 
to occur, amplification is less frequent than point mutations [28], and in clinical settings, 
this resistance mechanism is associated with increased BCR-ABL1 transcription [22]. Some 
authors hypothesized that this amplification or overexpression of BCR-ABL1 precedes the 
emergence of point mutations in the kinase domain [29]. 
2.2. DNA Damage Repair and Genomic Instability 
The DNA damage response (DDR) deregulation that leads to DNA damage and ge-
nomic instability has been implicated in the CML evolution, leading to TKI resistance and 
disease transition from CP-CML to more malignant stages [48–50]. This fact is supported 
by the higher frequency of copy number alterations and numerical and structural chro-
mosomal changes observed in CML patients in BC compared with those in CP—a sign of 
increasing genomic instability [49]. Genetic instability is also a common feature in TKI-
refractory CML patients [50]. The presence of 3q26.2 abnormalities, a minor route for ad-
ditional chromosomal abnormalities (ACAs), are associated with TKI resistance and poor 
prognosis [51]. The frequency of ACAs increases from 5 to 7% in CML patients in CP up 
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to 70 to 80% in BC and around 17% in TKI resistant patients, emphasizing the role of DDR 
dysregulation in the CML course and TKI resistance [52–54]. 
The BCR-ABL1 oncoprotein is responsible for the genomic instability observed in 
CML since its activity generates reactive oxygen species (ROS), disrupts the DDR path-
ways activating error-prone DNA repair, induces replication stress and centrosomal dys-
function, and inhibits apoptosis resulting from different DNA damage-induced lesions 
[50,55,56]. Although the activation of DNA damage repair pathways is increased to coun-
teract DNA damage, unfaithful and error-prone pathways such as alternative non-homolo-
gous end joining (NHEJ), single-strand annealing (SSA), and unfaithful homologous recom-
bination repair (HRR) are enhanced in Ph-positive cells [57–62]. In these cells, the usually 
faithful HRR induces point mutations, the NHEJ promotes extensive nucleobase loss, and 
the high activity of SSA generates large deletions [54]. Additionally, other DNA damage 
repair pathways are inhibited, including mismatch repair (MMR) and base excision repair 
(BER) [63–67], while the mutagenic nucleotide excision repair (NER) is promoted [68].  
Some studies performed in cell lines demonstrated the involvement of DDR in TKI 
resistance. The upregulation of the alternative NHEJ factors PARP1, WRN, and DNA lig-
ase IIIa along with the downregulation of the canonical NHEJ proteins Artemis and DNA 
ligase IV reflect the role of the inefficient and error-prone alternative NHEJ pathway in 
TKI resistance [69,70]. Furthermore, different in vitro models of TKI resistance showed 
upregulation of the BER genes MBD4 and NTHL1 [71,72]. Similarly, studies comparing 
sensitive and resistant Imatinib CML patients demonstrated that patients resistant to ther-
apy have higher expression levels of DNA damage repair genes such as RAD51L1, 
FANCA, and ERCC5 [73–75]. These facts support that DNA damage repair impairment in 
CML is directly involved in TKIs resistance and CML evolution. Importantly, the dysreg-
ulation of these mechanisms can also contribute indirectly to resistance through genetic 
instability and the consequent accumulation of point mutations and chromosomal aber-
rations. These point mutations can occur in the ABL1 kinase domain preventing the bind-
ing of TKIs. Moreover, point mutations and chromosomal aberrations can lead to the ac-
tivation of alternative cellular signaling pathways that also contribute to TKI resistance, 
such as PI3K/AKT, JAK/STAT, RAS/MAPK, and SRC pathways [18]. 
2.3. Drug Transporters 
Treatment efficacy is highly dependent on the access of the drug to its molecular tar-
get. For targeting BCR-ABL1 (a non-receptor tyrosine kinase), it is critical for TKIs to reach 
the inside of CML cells at adequate pharmacological concentrations to achieve therapeutic 
clinical outcomes. The movement of drugs across cell membranes is largely mediated by 
drug transporters proteins [76]. The balance between drug influx and drug efflux is crucial 
to BCR-ABL1 inhibition by TKIs, and changes on these transporters may explain the re-
sistance phenotypes caused by ineffective TKI uptake and/or excessive extrusion of TKI 
from the cell [76,77]. 
Most drugs have a low ability to diffuse freely across cell membranes, as their move-
ment is not dependent on ATP and is mediated by solute carrier (SLC) transporters, such 
as OCT1 [78]. OCT1 is the main drug transporter responsible for the TKI uptake, and its 
expression or activity impacts drug response levels [76]. This protein is encoded by the 
SLC22A1 gene, and higher mRNA levels were associated with major molecular responses 
[79,80]. On the contrary, low OCT1 expression is a common trait in multidrug resistance 
and is associated with suboptimal responses [81,82]. Some authors have identified the 
functional activity of OCT1 in leukemic cells at diagnosis as a prognostic marker of TKI 
response [83]. However, the results obtained regarding OCT1 expression and activity are 
controversial since many authors fail to observe a significant correlation with Imatinib 
transport or response [84]. Other transporters have been identified as mediators of TKI 
transport, namely OCTN2, OATPs, and MATE1 [78,85,86]. Harrach et al. proposed that 
measurement of MATE1 expression levels before treatment can help in identifying 
Imatinib non-responder patients [86]. In Imatinib-resistant cell lines, Alves et al. observed 
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a parallel decrease in OCT1 and OCTN2 expression showing the contribution of more 
than one influx transporters to the resistance process [87]. Lower levels of TKI uptake 
could be overcome with a switch to Dasatinib since this TKI can cross the cell membrane 
by diffusion [88,89]. 
Extrusion of metabolites, xenobiotics, and chemotherapeutic agents is mediated by 
ATP-binding cassette (ABC) transporters [77,90]. Overexpression of these transporters re-
duces the intracellular drug concentration, affecting its effectiveness [91]. P-glycoprotein 
(P-gp) is the most studied transporter, and its overexpression has been described in sev-
eral chemo-resistant cancers [76]. All TKIs approved for CML treatment are recognized 
substrates of P-gp [92]. High ABCB1 expression levels (the gene that encodes P-gp) are 
associated with poor long-term outcomes and advanced-phase disease [18,93,94]. Accord-
ing to Eadie et al., in the dynamic process of resistance acquisition, the P-gp overexpres-
sion may work as an initiator process that favors the development of another mechanism 
of resistance [95]. Another essential transporter for TKI resistance is the breast cancer re-
sistance protein (BCRP), codified by the ABCG2 gene [96]. This protein is present in stem 
cells, and its function is particularly relevant on LSCs, protecting them from TKI action 
[97,98]. As described for P-gp, high levels of BCRP are associated with resistance, while low 
rates are correlated with molecular response [99,100]. Additionally, other ABC transporters 
may be involved in TKI extrusion as MRP6 (ABCC6), which share some substrates with P-
gp. The MRP6 may be especially relevant in resistance to second-generation TKI [101]. 
Genetic variants highly influence the function, expression, and localization of drug 
transporters. The presence of polymorphic variants in genes actively involved in TKI 
transport may influence its pharmacokinetics and, consequently, drug efficacy [77,102]. 
For ABCG2, rs2231142 results in loss of function mainly by altering protein folding, and a 
significant reduction of the transporter has been linked to the presence of the A allele [103–
105]. Many groups found an association of the A allele with higher molecular response 
rates, while the CC genotype was correlated with TKI resistance [106–108]. Moreover, the 
G allele in rs683369 of SLC22A1 has been previously associated with lower major molec-
ular responses (MMR) and high risk of resistance due to low expression of OCT1 and 
consequent lower TKI uptake [107,109,110]. Thus, lower drug uptake or high drug extru-
sion may create a favorable environment for CML cells acquiring other resistance mecha-
nisms, such as BCR-ABL1 mutations [23,111]. 
2.4. Alternative Signaling Pathways 
To overcome the inhibition of BCR-ABL1, CML cells may activate alternative signal-
ing pathways to compensate the loss of BCR-ABL1 kinase activity. Consequently, cells 
will be able to proliferate and survive despite effective BCR-ABL1 inhibition. RAS/MAPK, 
SRC, JAK/STAT, and PI3K/AKT are some of the pathways that contribute to TKI resistance 
(Figure 2). 
GAB2 is one member of the GAB family docking proteins that exerts a critical role in 
CML by amplifying BCR-ABL signaling [112]. Dysregulation of this protein results in in-
creased proliferation, reduced growth factor requirements, and enhanced cellular motility 
[112]. Additionally, persistent phosphorylation of GAB2 results in activation of substrates 
such as RAS protein that stabilizes in the active form after GAB2 activation [113,114]. The 
increased expression of protein kinase C (PKC) was also observed in TKI-resistant CML 
cells [115]. In a recent study, Ma and collaborators demonstrated that PKC-β overexpres-
sion was associated with resistance to TKIs and its inhibition in CML CD34+ cells increased 
the sensitivity to Imatinib [115].  




Figure 2. Alternative to BCR-ABL1 signaling network. To evade BCR-ABL1 inhibition, CML cells activate alternative sig-
naling pathways including RAS/MAPK, SRC, JAK/STAT, WNT/b-catenin, hedgehog, and PI3K/AKT. The transduction of 
oncogenic signals culminates with the activation of multiple downstream signaling pathways that enhance survival, in-
hibit of apoptosis, and alter cell adhesion and migration. A subset of these pathways and their constituent transcription 
factors (β-catenin, Gli, STAT5, MYC, FOXO3), serine/threonine-specific kinases (RAS/MAPKs, PI3K/AKT/mTOR), and 
apoptosis-related proteins (BAD, BCL-2, BCL-XL, survivin) are shown. It is important to note that this is a simplified 
diagram and that many more associations between BCR-ABL1 and signaling proteins have been reported. 
Overexpression of the SRC family kinase protein, such as LYN and HCK, are related 
to CML resistance cases [5,116]. Therefore, the activation of SRC function is crucial for cell 
proliferation, survival, and adhesion, and is a compensatory mechanism in the case of 
BCR-ABL1 inhibition [117]. These SRC proteins lead to AKT activation promoting sur-
vival and STAT5 activation stimulating proliferation [118]. The overexpression of SRC 
proteins in CML was the rationale for development and use of dual SRC/ABL inhibitors, 
such as Dasatinib and Bosutinib [5]. Additionally, STAT signaling can be activated 
through the JAK2 protein. In response to cytokines released by cancer cells and bone mar-
row niche cells, JAK2 is activated and subsequently phosphorylate one of the seven STAT 
members [119]. STAT3 and STAT5 have been identified as the most relevant STAT pro-
teins in cancer [119]. After STAT phosphorylation, this protein migrates to the nucleus 
regulating the transcription of various target genes, e.g., c-MYC. In CML, STAT5 is in-
volved in disease progression, promoting cell cycle progression and ROS production, in-
hibiting apoptosis, and up-regulating P-gp expression [120]. Due to its pleiotropic effects, 
low levels of STAT5 have been correlated with TKI sensitivity. On the other hand, STAT3 
emerges as a critical molecule in the resistant phenotype, including TKI resistance [121]. 
Phosphorylation of STAT3 on residue 727 and STAT5 in residue 694 is reduced under 
treatment with TKIs, but the phosphorylation on residue 705 of STAT3 is not altered [122].  
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After activation of PI3K, AKT is subsequently phosphorylated, influencing multiples 
downstream proteins. BAD is one of AKT targets that reduces the apoptotic signal. After 
being phosphorylated, BAD becomes inactive and consequently did not inhibit anti-apop-
totic proteins like BCL-2 and BCL-XL [123]. Another AKT target is the FOXO transcription 
factors, which under normal conditions regulate cell cycle arrest and apoptosis. The AKT 
induced phosphorylation of FOXO blocks its activity avoiding apoptosis and promoting 
cell cycle progression [124]. Furthermore, mTOR is a serine/threonine kinase that is acti-
vated by AKT and regulates mRNA translation, controlling cell growth and proliferation 
[125]. In the same way, NF-kB is also indirectly activated by AKT, promoting gene tran-
scription. AKT targets IKK, the natural inhibitor of NF-kB, releasing this repression signal 
from NF-kB that can then translocate into the nucleus acting as a transcription factor [126]. 
Furthermore, CML patients resistant to TKIs and Imatinib-resistant cell lines show 
higher survivin levels than the sensitive ones [127]. Survivin is an inhibitor of apoptosis 
protein (IAP), downstream of the BCR-ABL1 signaling pathway, known to regulate the 
cell cycle and apoptosis, favoring the survival of cancer cells by evading cell death and 
promoting cell division [128]. Zhou et al. showed that a combination treatment of a 
WNT/β-catenin signaling inhibitor with Nilotinib synergistically killed KBM5T315I cells (a 
CML resistant cell line) as well as primary BC-CML cells obtained from TKI-resistant pa-
tients (with and without BCR-ABL1 kinase mutations) by decreasing the expression of 
CD44, MYC, p-CRKL, p-STAT5, and survivin [129]. 
Additionally, all signaling pathways mentioned along with the BCR-ABL1 activity 
itself lead to an accumulation of ROS in CML cells [130,131]. Some studies reported in 
primary BCR-ABL1-positive cells up to six times more ROS levels than in normal cells 
[132]. This oxidative cellular milieu contributes to a higher genetic instability potentially 
leading to an increased probability of point mutations [70,133]. The unsatisfactory re-
sponse rates to TKIs and therapy failure observed in some patients can occur due to mu-
tations downstream of BCR-ABL1 or in compensatory alternative signaling pathways (see 
above) [24]. In CML-BC patients, several additional genetic abnormalities have been de-
tected. These abnormalities (among others) include: (I) mutations: IKZF1, RUNX1, ASXL1, 
BCORL1, and IDH1/IDH2; (II) fusions: MLL, MSI2, and MECOM; (III) deletions: 
PAX5/CDKN2A, HBS1L-MYB, and del(17p); (IV) amplifications: chromosome 8, 19, and 
17q [134,135]. These mutations, along with epigenetic reprogramming, facilitate the BCR-
ABL1 independent activation of PI3K, MAPK, JAK/STAT, and SRC signaling pathways in 
CML cells, all of which have been implicated in BCR-ABL1 independent mechanisms of 
resistance [22]. However, the detection of the signaling pathway responsible for the re-
sistant phenotype is in many cases difficult, hampering the discovery of a suitable target 
to use in combination with TKI to circumvent resistance. 
The impairment of multiple signaling pathways induced by BCR-ABL1 or by inde-
pendent mechanisms results in a favorable cancer environment, contributing to poor TKI 
efficacy and consequently to resistance. The knowledge of this network supports the ra-
tionale to new therapeutic schemes with other inhibitors or in combination with TKIs. 
2.5. Stem Cell Metabolism and Pathways 
The LSCs display high resistance to TKI showing heterogenous adaptations includ-
ing a modified transcriptome, genome, and epigenome [136]. Given the extensive diver-
gence of the numerous BCR-ABL oncogene-independent pathways that are deregulated 
in LSCs, it is not surprising that cellular metabolic reprogramming (an emerging hallmark 
for cancer stem-cell biology) [137] has been also implicated in LSC survival adaptations 
and resistance to TKI treatment. Specifically, while normal cells mostly exploit glucose for 
producing energy via mitochondrial oxidative phosphorylation (OxPHOS), cancer cells 
may switch to increased rates of glucose uptake and aerobic glycolysis, a process also 
known as the Warburg effect [138]. OxPHOS is critical for energy production as well as 
for supplementation of anabolic precursors in LSCs [139], representing thus a vulnerabil-
ity that can be targeted by selective therapeutics. On the other hand, the low O2 tension 
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(hypoxia) that characterize the bone marrow microenvironment (BMM) niches stabilizes 
hypoxia-inducible factor 1 (HIF-1) which is a crucial regulator of maintenance, sur-
vival, and proliferation of LSCs [140]. 
The BCR-ABL1-mediated activation of the nutrient-sensitive pathways leads to 
GSK3-β suppression along with the cytosolic retention and degradation of FOXOs, a num-
ber of pleiotropic transcription factors that (among others) are activators of autophagy 
[141]. Upon treatment with TKIs the PI3K/AKT signaling is blunted in CML (including 
LSCs) leading to inhibition of the pro-survival β-catenin signaling [142]; yet it also enables 
activation of FOXOs, likely offering to LSCs a BCR-ABL1-independent route for survival. 
In support, FOXO signaling maintains LSCs in a CML-like myeloproliferative disease 
mouse model [143]. The autophagic process also generates adenosine triphosphate (ATP) 
and essential building blocks (e.g., amino acids) during oxygen and/or nutrient depriva-
tion [144]. Thus, it is not surprising that it essentially helps tumor cells (including LCSs) 
to tolerate metabolic stress (e.g., triggered by TKIs) [145] and/or suppress apoptosis in-
duced by anti-tumor agents [146]. Interestingly, basal autophagy is higher in CML-LSCs as 
compared to normal HSCs and it is further upregulated following treatment with TKIs. As 
expected, inhibition of autophagy enhances the selective anti-tumor activity of tigecycline 
to overcome drug resistance in CML [147], and effective inhibition of autophagy using sec-
ond generation autophagic inhibitors potentiates TKI-induced cell death of LSCs [148]. 
Metabolomics studies have shown that LSCs accumulate high levels of various di-
peptides consisting of a range of amino acids [149]. Given the LSCs’ need for essential 
building blocks, the internalization of dipeptides and oligopeptides is an energy-saving 
process that supplies intracellular amino acids. This mechanism is related to the upregu-
lation of the oligopeptide/dipeptide transporter SLC15A2 which, by supplying dipep-
tides, activates the p38/MAPK-Smad3-FoxO3a axis [149]. Similarly, the branched-chain 
amino acid (BCAA) valine is central to HSC self-renewal capacity [150] and the BCAA 
levels were significantly increased in these cells in a CML-BC mouse model. This increase 
is due to the upregulated expression and activity of the BCAA amino acid transaminase 1 
(BCAT1) [151]. Notably, increased metabolism of BCAA activates mTORC1 that acts as a 
pro-survival pathway of BC-CML-initiating cells [151]. 
Regarding regulation of the tricarboxylic acid (TCA) cycle and OxPHOS, a compara-
tive gene expression analysis in CML stem-progenitor cells isolated from TKI-responding 
and non-responding patients revealed upregulation of ILK (integrin-linked kinase) in 
LSCs of non-responding patients [152]. It was shown that ILK regulates quiescence of non-
responding LSCs through the OxPHOS pathway [152]. The multifunctional sirtuin 1 
(SIRT1) was also found to be induced in CML-LSCs and contributes to their resistance to 
TKIs [153]. The upregulated mitochondrial OxPHOS is an important survival mechanism 
of CML-LSCs [139]. Supportively, deficiency of the Sirt1 gene downregulated OxPHOS-
related mRNAs in LCSs and delayed CML onset and progression in a mouse CML model 
[154]. Mechanistically, it was found that loss of SIRT1 reduced PGC-1α acetylation result-
ing in suppressed OxPHOS activity [154]. Further to these findings it was shown that tar-
geting mitochondrial OxPHOS via tigecycline suppressed the mitochondrial respiration 
and the proliferative capacity of therapy-resistant CML-LSCs [139]. Moreover, analysis of 
patient-derived LSCs revealed increased aerobic ATP production which correlated with 
high expression and activity levels of pyruvate carboxylase [139]. Hif-1a knockout in a 
mouse model suggested that Hif-1a enhanced glycolysis and possibly contributes to CML 
stem-cell survival [140]. 
Lipids and fatty acid metabolism are also involved in LSCs survival, since arachi-
donate 5-lipoxygenase (encoded by arachidonate 5-oxygenase, Alox5) was found to be 
upregulated in LSCs and modulate β-catenin levels in a BCR-ABL1-independent manner 
[155,156]. Interestingly, both Alox5 and arachidonate 15-oxygenase (Alox15) are overex-
pressed in CML stem cells and are not suppressed by TKIs [156,157]. Moreover, loss of the 
Alox5 gene impaired LSCs and prevented CML development [156] while activation of the 
PKC-β/Alox5 axis promoted BCR-ABL1-independent TKIs resistance in CML [115]. 
Cancers 2021, 13, 4820 11 of 37 
 
 
Alox5- or Alox15-deficiency in mice resulted in decreased self-renewal capacity of CML 
stem cells as well as in reduced rates of CML onset [156,157]. 
2.6. Epigenetic Alterations 
There is now ample evidence that epigenetic dysregulation contributes to leukemic 
stem cell generation, maintenance, and progression in CML. Several studies have demon-
strated that mutations in epigenetic regulating genes, such as DNMT3A [158], TET2 [159], 
EZH2 [160], and ASXL1 [160], are relatively uncommon in chronic phase CML [160] but 
the incidence of these mutations increase during disease progression [161,162]. 
Epigenetic modifications consist in the addition or removal of small molecules, such 
as methyl or acetyl groups, onto DNA or DNA-related proteins, such as histones, resulting 
in the remodeling of chromatin and providing sites for the recruitment of other transcrip-
tion factors [163]. In addition to the modification in nuclear molecules, post-translational 
modifications may also have a significant effect on the phenotype of CML and its respon-
siveness to therapy [164]. DNA hypermethylation is a common oncogenic process in many 
solid and hematological tumors. This has been well documented in CML patients, espe-
cially those with AP and BC [160,165]. Although ABL-1 hypermethylation has been well 
documented, its role in the pathophysiology of disease progression is not clear. It is, how-
ever, evident that increased methylation of genes such as p15 [166], RASSF1A [167], 
TFAP2A [168], and EBF2 [168], among others, is a frequent event in disease progression 
[169,170]. This is in line with what is observed in myelodysplastic syndrome (MDS) and 
acute myeloid leukemia (AML), especially secondary AML and AML with MDS-related 
changes [171]. 
In parallel to DNA hypermethylation, malignant tissues also acquire histone modifi-
cations. The most frequent of these are acetylation, methylation, and phosphorylation. 
Their main effect is the modulation of chromatin condensation which subsequently alters 
expression of cell cycle, apoptotic, and tumor suppressor genes [172]. Specific enzymes reg-
ulate these processes and the histone acetyl-transferases (HAT) and histone deacetylases 
(HDAC) are the best studied ones. In general, deacetylation of histones leads to silencing of 
genes in the affected locus. Increased expression of HDAC has been documented in several 
malignant cells, including CML, resulting in loss of the tumor suppressor scaffold/matrix 
attachment region binding protein 1 (SMAR1) [173], which in turn increases cyclin D1 ex-
pression, and suppresses p53 [174], impeding its regulation of the cell cycle. 
Recent research has uncovered that, in addition to epigenetic regulation at a nuclear 
level, post-translational processes play a critical role in epigenetic regulation of protein 
synthesis. MicroRNAs are the main mediators of these processes, exerting their effect by 
blocking protein synthesis and promoting mRNA degradation [164]. CML patients exhibit 
clearly distinct microRNA expression patterns compared to healthy individuals and pat-
terns of microRNA expression also differ between CML patients in different phases of the 
disease and between those that do and do not respond to TKI [175]. One such example is 
miR-150, which is downregulated in CML patients at diagnosis as compared to healthy 
individuals and in advanced phases of disease as compared to CP [176,177]. Interestingly, 
patients who respond to TKI increase miR-150 levels to levels seen in the normal popula-
tion. Similar findings were observed for miR-146a [178] and miR-10a [179], with reduced 
levels seen at diagnosis and in advanced phases and normal levels in patients who re-
spond to TKI. In Imatinib-resistant CML K562 cells (K562-RC and K562-RD cells), the on-
comiRs miR-21 and miR-26b were upregulated and the tumor suppressor miR-451 was 
downregulated in comparison with sensitive cells [180]. Other mi-RNAs, such as miR-19a, 
miR-19b, miR-17, miR-130, and miR-150, are increased in CML [181,182]. The expression 
of some of these miRs is directly regulated by BCR-ABL1 through its effect on miR effec-
tors, such as MYC in the case of miR-17 [183], CCN3 in the case of miR-130 [184], and MYB 
in the case of miR-150 [176]. Some miRs may also interact directly with BCR-ABL1, like 
miR-203 [185], which has an inhibitory effect on BCR-ABL1 and expression is suppressed 
in CML through hypermethylation. 
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2.7. CML Microenvironment and Immunological Status 
BMM is considered a safe haven for HSCs [186,187] and in CML, as described in other 
neoplasias, the leukemic cells become progressively independent of physiological control 
of BMM [188–190]. In addition, the leukemic cells shape the phenotype and function of 
surrounding cells, reprograming the BMM to a more favorable environment for leukemic 
cell survival, proliferation, immune escape, and drug resistance [191]. This type of re-
sistance could be mediated by changes in direct cell–cell contact, production/secretion of 
cytokines and growth factors, and/or the establishment of a hypoxic environment [192]. 
The bidirectional interaction between CML cells and the BMM niche is vital to sup-
port leukemic development and counteract the TKI effects [187,190]. Alteration in cell ad-
hesion to stroma may provide chemoprotection to CML cells [193]. Kumar et al. (2020) 
showed that BCR-ABL1 T315I mutated cells presented alteration in the actin cytoskeleton, 
integrin β3 levels, in the expression and phosphorylation levels of FAK and ILK, and fi-
bronectin expression when compared with BCR-ABL1 sensitive cells [194]. In CML, the 
increased expression of integrin β3 and ILK interaction with β integrins was associated 
with Imatinib resistance through the activation of PI3K/AKT, STAT3, and ERK1/2 signal-
ing pathways [152]. Furthermore, the interaction with MSCs can also be mediated by N-
cadherin and the activation of β-catenin signaling, which are crucial for LSC [195]. Dysreg-
ulation of cytokines, growth factors, and their receptors contribute to CML protective en-
vironment, leading to CML persistence and resistance to treatment [196,197]. These factors 
are partly due to the BMM component's activity, but also to CML cells through autocrine 
and paracrine signaling [196,197]. CXCL12, IL-3, VEGF, FGF, TNF-α, IL-6, IL-7, and TGF-
β, among others, are cytokines and growth factors altered in CML [198]. Studies have 
shown that CD34+ cells from patients with CML produce ten times more cytokines than 
their normal counterpart, highlighting the importance of these signaling molecules to this 
disease [198]. TKI treatment can reverse the levels of these soluble factors albeit not in a 
complete manner. Signaling from different cytokines, including of IL-7, acts through the 
JAK2/STAT pathway to balance apoptosis induced by TKI [119,199]. This culminates in 
sustained activation of STAT3, with increased expression of anti-apoptotic genes, e.g., 
BLC-2, BLC-XL, and MCL-1 [121]. CXCL12 signaling pathway is crucial for the mainte-
nance of healthy HSCs, but, in CML BMM the levels of CXCL12 are reduced. This pro-
motes the expansion of CML stem cells by increasing their self-renewal capacities 
[197,200]. Depending on the factors released, multiple pathways could be activated to 
avoid TKI effect. Another important pathway of cell communication is through microvesi-
cles release, which can transport different mRNAs, miRs, and proteins. One example is 
the communication of CML cells with HSCs. Through miR-146b transfer, microvesicles 
derived from the CML cell line K562 induced the transformation of HSCs into leukemic 
cells [201]. Similarly, CML cells interact with MSCs by increasing TGF-β1 in MSCs, which 
causes TGF-β1-dependent proliferation of BCR-ABL-positive cells as a feedback loop 
[202]. Furthermore, the hypoxic environment may also have implications for drug re-
sistance. Even with BCR-ABL1 inhibition, hypoxic conditions of BMM induce CML cells 
survival through the activation of HIF-1 signaling pathway [27,199]. 
The immune system is an essential player within the BMM, and expression of specific 
immune cells might dictate successful TKI responses [203,204]. At diagnosis, CML is char-
acterized by immune dysfunction, with a reduction in the number and function of NK 
and dendritic cells as well as dysfunctional CD8+ cytotoxic T cells [203,205]. Associated 
with these abnormalities, myeloid-derived suppressor cells (MDSCs) and regulatory T 
cells (Tregs) are increased, contributing to T-cell dysfunction. After TKI therapy, the levels 
of immune cells are restored to normal levels [203]. However, during disease progression 
and drug resistance, CML cells adopt strategies to escape immunosurveillance [191,206]. 
One example is the aberrant expression of immune checkpoint, such as molecules in the 
PD-1/PDL-1 axis, which has been associated with immune evasion. Overexpressed PDL-
1 on tumor cells will function as a co-inhibitory molecule for T cells (expressing PD-1), 
leading to T-cell exhaustion and anergy [206–208]. The creation of an immunosuppressive 
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and inflammatory BMM is crucial for LSC preservation and drug resistance. Leukemic 
cells induce the expansion/activation of MDSCs directly through the release of microvesi-
cles that will reprogram MDSC and indirectly through MSCs, which overexpress im-
munomodulatory factors (such as TGF-β, IL-6, and IL-10) capable of activating MDSCs. 
This culminates into increased Treg levels, T-cell inhibition, and dysfunction of NK cells 
[202,209]. The relevance of BMM and immunological status in CML was highlighted in 
TFR studies, where specific immune cell types have been proposed as predictive bi-
omarkers of successful TKI discontinuation [204,210,211]. 
3. Methodologies to Access TKI Resistance 
CML treatment optimization has been achieved by the implementation and stand-
ardization of molecular monitoring strategies such as real-time quantitative reverse tran-
scription polymerase chain reaction (RT-qPCR). The different methodologies used for 
CML diagnosis and treatment monitoring in the clinic have undeniably improved the ef-
fectivity of patients’ management, improved the detection of the BCR-ABL1 KD muta-
tions, and refined the selection of CML patients with higher probability to achieve treat-
ment-free remission (TFR) after TKI cessation. 
3.1. Molecular Approaches 
The BCR-ABL1 gene is, at the same time, both a therapeutic target and a robust and 
precise biomarker of minimal residual disease (MRD). Over the years, CML treatment has 
been optimized through the implementation and standardization of molecular monitor-
ing. According to the 2020 European Leukemia-Net (ELN) recommendations, the molec-
ular testing of CML should include different molecular methodologies [212]. At diagnosis, 
it is recommended to perform cytogenetics (chromosome banding analysis) to detect the 
Ph chromosome, fluorescence in situ hybridization (FISH) in Ph-negative patients, and 
qualitative PCR to identify the BCR-ABL1 fusion gene type. During treatment, the regular 
quantification of BCR-ABL1 transcripts by quantitative real-time PCR is performed to 
monitor transcript levels. After the achievement of a complete cytogenetic response, cyto-
genetic tests are warranted only in cases with ACA in the Ph+ clone [212]. These recom-
mendations also establish time-dependent molecular response (MR) milestones with 
prognostic significance, optimal response monitorization, and the foundations for treat-
ment-free remission (TFR). Deep molecular response (DMR) is considered of crucial clin-
ical importance to identify patients with a high probability to remain in remission after 
discontinuing TKI therapy [213]. In TFR, only quantitative PCR for BCR-ABL1 transcripts 
is needed [214]. The 2020 ELN recommendations defined more rigorous TFR criteria de-
manding typical BCR-ABL1 transcripts, a minimum of 4–5 years of TKI therapy, and a 
DMR of MR4 or better during more than 2 years [212]. The success of TKI discontinuation 
is mainly predicted by a durable DMR [215,216]. However, quantitative PCR might not be 
the best methodology to select CML patients for TKI discontinuation and for molecular 
monitoring during TFR, since the majority of patients (50–60%) with undetectable DMR 
by quantitative PCR eventually lose major molecular response (MMR) [215,217,218]. 
In clinical settings, some molecular tests have been robustly validated for detecting 
and monitoring BCR-ABL1 transcripts [213]. The "classical" quantitative PCR (RT-qPCR) 
has several intrinsic limitations, including the detection limit of three copies of BCR-ABL1 
transcript, the need for a standard curve, and the sensitivity to inhibitors. However, sev-
eral studies have tried to overcome these limitations by improving its performance [214]. 
Three recently FDA-approved tests seem to perform better than the standard RT-qPCR 
tests and are more attractive for monitoring very low levels of BCR-ABL1 transcripts [213]. 
These tests are the QuantideX® qPCR BCR-ABL IS Kit (Asuragen Inc., Austin, TX, USA), 
with a sensitivity of 0.002% IS (MR4.7) for CML patients expressing e13a2 or e14a2 fusion 
transcripts, the Xpert® BCR-ABL Ultra (Cepheid, Sunnyvale, CA, USA), which detects the 
most common BCR-ABL transcripts below MR4.5 or 0.0032% with a short turnaround time, 
and the digital PCR (dPCR) kit QXDx BCR-ABL %IS (Bio-Rad Laboratories Inc., Hercules, 
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CA, USA) [219–221]. This dPCR kit was compared with the gold standard RT-qPCR, and 
the assays were strongly correlated (r = 0.996) in the range between 20% to 0.002% [222]. 
These results supported the recommendation of dPCR as the standard of care for moni-
toring of patients with CML [214]. Moreover, a multicenter international study confirmed 
that dPCR is a valid alternative to RT-qPCR, showing a detection rate of 90.9% at MR4.5, 
81.2% at MR4.7 (0.002% BCR-ABL1/ABL1 level), and 81% at MR5.0, with a low interlabora-
tory variation and high assay linearity [214,223,224]. These data indicate the usefulness of 
dPCR for MRD monitoring, particularly in CML patients with low BCR-ABL1 levels and 
those potentially eligible for TKI discontinuation. However, to successfully implement 
dPCR in clinical settings, this methodology should be optimized and standardized to 
CML MRD monitoring. 
Additionally, molecular testing is crucial in the setting of TKI therapy failure since 
these patients may have acquired BCR-ABL1 point mutations that impair TKI binding 
[214]. The gold standard for BCR-ABL1 KD mutation screening is Sanger sequencing, but 
this technique has relatively poor sensitivity (10–20%). The clonal configuration of BCR-
ABL1 mutations is very important since compound mutations are extremely resistant to 
first, second, and even third-generation TKIs in some cases [41,213–215]. In the context of 
BCR-ABL1 point mutations, next-generation sequencing (NGS) and dPCR are being in-
vestigated as alternative methodologies to Sanger sequencing. The NGS approach has bet-
ter sensitivity (1%) than Sanger and can distinguish between compound and polyclonal 
BCR-ABL1 mutations when multiple substitutions fall on the same sequence reads. How-
ever, this methodology has a high error rate, particularly when sequencing mRNA, due 
to the use of the error-prone reverse transcriptase [213]. Recently, NGS was shown to de-
tect emerging mutations and to predict high-risk transformation, highlighting the im-
portance of low-level mutations—mutations with a variant allele frequency of 3–20%—in 
clinical settings [39,225]. The advantages of NGS to detect BCR-ABL1 KD mutations re-
sulted in its inclusion in position papers and the 2020 ELN recommendations 
[212,226,227]. As mentioned, the dPCR has also been explored as a complementary or even 
alternative strategy to detect BCR-ABL1 KD mutations. Soverini and collaborators (2019) 
compared Sanger sequencing, NGS, and dPCR in CML patients with failure or warning 
responses to TKI therapy [228]. In this study, a multiplex single-tube assay was used to 
detect and quantify mutations conferring resistance to one or more second generation 
TKIs (T315I/A, F317L/V/I/C, Y253H, E255K, F359V/I/C, E255V, and V299L) and showed a 
very good concordance between dPCR and NGS, independently of mutation type and 
variant allele frequency, in samples positive for second-generation TKI-resistant muta-
tions. However, NGS remains a better methodology to detect emerging mutations due to 
the high number of different mutations that can confer resistance to TKIs [214,228]. 
3.2. Bioinformatics and Artificial Intelligence as Methodologies to Decipher Mechanisms of 
Action or Resistance to TKIs in Leukemia 
The use and application of machine learning methods for the diagnosis of common 
types and subtypes of leukemia has been very successful over the past decades, as re-
viewed by Sarah et al. [229]. One of the most comprehensive efforts was accomplished ten 
years ago using genome-wide expression profiling in the diagnosis and subclassification 
of many different types of leukemias [230]. Following this line of research, artificial intel-
ligence (AI) and machine learning (ML) methods have been proven to be also very useful 
for integrating large-scale-omics data from cancer patients and for analyzing gene expres-
sion profiles in response to different drugs [231]. In this scenario, positive associations 
between gene expression and anticancer drug activity allowed the discovery of gene tar-
gets for the drugs tested [232]. Conversely, a negative association between gene expres-
sion and drug activity measured in these assays (for example, detecting high expression 
of a gene corresponding to decreased activity of a drug) indicated that such a gene/protein 
could be mediating resistance and low sensitivity to the drug. These associations have 
been found using ML by Lee et al. [233], who identified molecular markers for targeted 
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treatment of AML. They also found that high expression of GPR34 and ADRBK2 genes 
(encoding two G protein-coupled receptor kinases) was correlated with a lower activity 
of Sunitinib (a multi-targeted receptor tyrosine kinase, RTK, inhibitor). 
A recent study that also used ML models was able to predict future diagnosis of CML 
based on the analysis of data from retrospective electronic health records [234]. In partic-
ular, the ML models could predict CML using blood cell counts prior to diagnosis. These 
findings indicate that a ML model trained with blood cell counts can lead to diagnosis of 
CML earlier in the disease course as compared to usual medical care [234]. Other authors 
have recently developed a leukemia artificial intelligence program (LEAP) using the Ex-
treme Gradient Boosting (XGBoost) decision tree method for the optimal treatment rec-
ommendation of tyrosine kinase inhibitors (TKIs) in patients with CML-CP. This work 
reports that the AI method consistently won international data analysis challenges select-
ing the optimal frontline TKI with accurate prediction [235]. These recent examples show 
that the development of ML algorithms outperforms conventional statistical models in 
prediction accuracy, paving the way for a new era of personalized treatment recommen-
dations for cancer patients. 
4. Therapeutic Approaches against Resistance 
During the treatment of a patient with CML, changes in therapeutic protocol may be 
due to several reasons: resistance, intolerance, or suboptimal response rates (warning cri-
teria), causing a mandatory TKI switch in case of resistance. The selection of the best sec-
ond-line therapy needs to be adjusted to patients’ characteristics, comorbidities, and tox-
icity of first-line TKI, among other factors [212]. Different strategies can be adopted to 
overcome the resistant phenotype and reestablish response rates, or even in some cases, 
to improve the probability of treatment-free survival. From BCR-ABL1 targeted therapies 
to other signaling pathway inhibitors or immunotherapies, multiple options have been 
explored in resistant CML not only in monotherapy but also in combination strategies 
(Table 2). 
Table 2. Selected clinical trials of different therapeutic strategies in CML. 
Drug Class/Mechanism of Action NCT Number Scheme Phase 
BCR-ABL1 therapies    
Asciminib ABL1 myristoyl pocket inhibitor NCT02081378 Mono. and Comb. TKI 1 
  NCT03595917 Plus Dasatinib 1 
  NCT03906292 Mono. and Comb. TKI 2 
  NCT03578367 Plus Imatinib 2 
  NCT03106779 Mono. 3 
  NCT04971226 Mono. 3 
  NCT04948333 Mono. 3 
  NCT04877522 Mono. and Comb. TKI 3 
  NCT04795427 Mono. 2 
  NCT04666259 Mono. 3 
Flumatinib BCR-ABL1 ATP-binding site inhibitor NCT04677439 Mono. 4 
  NCT04933526 Mono. 4 
PF-114 BCR-ABL1 ATP-binding site inhibitor NCT02885766 Mono. 1/2 
HQP1351 BCR-ABL1 ATP-binding site inhibitor NCT03883100 Mono. 2 
  NCT03883087 Mono. 2 
  NCT04126681 Mono. 2 
  NCT04260022 Mono. 1 
Vodobatinib BCR-ABL1 ATP-binding site inhibitor NCT02629692 Mono. 1/2 
Non BCR-ABL1 therapies    
BP1001 
GRB2 antisense oligonucleotide 
NCT01159028 Mono. 1 
 NCT02923986 Plus Dasatinib 2 
Tipifarnib Farnesyltransferase inhibitor NCT00004009 Mono. 1 
Lonafarnib Farnesyltransferase inhibitor NCT00047502 Plus Imatinib 1 
Selumetinib MEK inhibitors NCT03326310 Plus Azacitidine 1 
Ruxolitinib JAK2 inhibitor NCT03610971 Comb. TKI 2 
  NCT01702064 Plus Nilotinib 1 
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Everolimus mTOR inhibitor NCT00081874 Mono. 1/2 
  NCT01188889 Plus Imatinib 2 
Sirolimus mTOR inhibitor NCT00776373 Plus Citarabine 1/2 
Venetoclax BCL-2 inhibitor NCT02689440 Plus Dasatinib 2 
  NCT04188405 Plus Ponatinib, Decitabine 2 
  NCT03576547 Plus Ponatinib, corticosteroids 1/2 
AMG-232 MDM2 inhibitor NCT04835584 Mono. 1/2 
Sonidigib SHH inhibitor NCT01456676 Plus Nilotinib 1 
Pioglitazone PPAR-γ inhibitor NCT02852486 Plus Imatinib 2 
  NCT02767063 Plus TKI 1/2 
  NCT02889003 Plus TKI 2 
Epigenetic modulators    
Azacitidine Hypomethylating agent NCT03895671 Plus Ponatinib 2 
  NCT01460498 Plus TKI 1 
Panobinostat Histone Deacetylase Inhibitor NCT00451035 Mono. 1 
Immunotherapies    
Peg-IFNα Pegylated Interferon alpha NCT01866553 Plus Nilotinib 2 
  NCT01872442 Plus Dasatinib 2 
  NCT03831776 Plus Bosutinib 2 
Nivolumab Anti-PD-1 antibody NCT02011945 Plus Dasatinib 1 
  NCT01822509 Plus Ipilimumab 1 
Pembrolizumab Anti-PD-1 antibody NCT03516279 Plus TKI 2 
DC vaccine Dendritic cells vaccine NCT02543749 Mono. 1/2 
CLL1-CD33 cCART compound CAR (cCAR) T cells NCT03795779 Mono. 1 
KDS-1001 natural killer cell therapy NCT04808115 Plus TKI 1 
Comb: combination; Mono: monotherapy; NCT: national clinical trial number; TKI: tyrosine kinase inhibitors. 
4.1. BCR-ABL1 Targeted Therapies 
All TKIs approved for CML treatment are orally administrated and competitively 
inhibit BCR-ABL1 TK by binding at the ATP-binding site. Dasatinib, Nilotinib, Bosutinib, 
and Radotinib are second-generation TKIs, where Ponatinib is a third-generation TKI. 
According to ELN guidelines, in case of resistance, the BCR-ABL1 KD mutation pro-
file needs to be investigated to guide selecting the second line of treatment. Each TKI pre-
sents a different sensitivity profile to the different mutations identified (Table 1), where 
the first designed TKI (Imatinib) presents less potency in case of resistance [27,34,35]. All 
the approved next-generation TKIs were designed aiming reverse resistance and intoler-
ance observed in patients treated with Imatinib, especially the point mutations identified 
as a critical factor for TKI efficacy. Dasatinib can bind to BCR-ABL1 in active and inactive 
conformation. This dual SRC/ABL1 inhibitor in vitro showed over 300-fold more potency 
than Imatinib and can also inhibit SRC family kinases [236], being recommended in the 
case of Y253H, E255V/K, and F359V/I/C mutations [212]. However, the toxicity profile of 
Dasatinib, particularly associated with pleural effusion and pulmonary hypertension, 
needs to be considered according to patient characteristics [237]. In opposition, Nilotinib 
results from a chemical modification of Imatinib, and in vitro has approximately 30-fold 
higher potency than first-generation TKI. Nilotinib binds to inactive conformation of BCR-
ABL1, like Imatinib, but also targets PDGFR and c-KIT [238]. 
The resistance pattern to Nilotinib is very similar to that observed for Imatinib re-
garding drug transporters, but this second-generation TKI presented a different resistance 
profile to BCR-ABL1 point mutations. Nilotinib is resistant to Y253H/F, E255K/V, and 
T315I [27,34,35,93] but is an alternative for second line treatment in cases of other muta-
tions. Very similar to Nilotinib, the Korean approved TKI (Radotinib) presented an in vitro 
IC50 of 34 nM [41,239]. Nevertheless, cases of Radotinib resistance have been associated 
with BCR-ABL1 point mutations, namely Y235H, E255V, T315I, and T315M [239] (Table 
1). Bosutinib, a second-generation TKI, is a dual SRC/ABL1 kinase inhibitor that binds to 
BCR-ABL1 in both conformations, as described for Dasatinib [240,241]. In terms of recom-
mendations as to which TKI should be used in the case of BCR-ABL1 resistance mutations, 
Bosutinib works for all identified mutations with the exceptions of V299L and T315I BCR-
ABL1 point mutations [27,34,35] (Table 1). 
Cancers 2021, 13, 4820 17 of 37 
 
 
The most aggressive point mutation identified in BCR-ABL1 is the T315I, and 
Ponatinib was designed to overcome this mutation. Ponatinib is the only TKI recommend 
by the European LeukeniaNet for the T315I mutation and can also be used in F317L/V/I/C, 
T315A, and V299L. In vitro, Ponatinib presented 500 times more potency than Imatinib 
and binds to the inactive conformation of BCR-ABL1 [242]. Nevertheless, resistance to this 
third-generation TKI has been associated with compound mutation of BCR-ABL1, even 
those including T315I, and with influx and efflux drug transporters, such as P-gp and 
BCRP [32,41]. 
Asciminib is the first STAMP (specifically targeting the ABL1 myristoyl pocket) in-
hibitor that has granted breakthrough therapy designation by FDA in 2021. This approval 
was based on ASCEMBL trial results and intend to adult Ph-positive CML in CP previ-
ously treated with two or more TKIs or patients harboring the T315I mutation. In opposi-
tion to the previously described TKI, Asciminib targets the myristoyl site of ABL1 kinase 
with an in vitro IC50 of 1–20 nM and from 40 to 200 mg twice a day in trials [46,243,244]. 
By targeting different portions of ABL1 kinase, Asciminib may be very useful to overcome 
TKI resistance mediated by point mutations previously mentioned (Section 2.1). However, 
for this TKI were already identified mechanisms that could lead to resistance, namely 
point mutation at myristylation pocket (V468F and I502L) and the function of ABC trans-
porters [245,246]. Due to different mechanisms of action on the same kinase, the combina-
tion of the other approved TKI with Asciminib has been explored with the aim to reduce 
the possible appearance of BCR-ABL1 mutant clones [37,247]. 
New TKIs have been designed to overcome ABL1 gatekeeper mutations (mainly 
T315I) and at present are only preclinically validated inhibitors, such as Bafetinib, Rebas-
tinib, Tozasertib, and Danusertib [248]. Other new molecules are already under clinical 
trials e.g., PF-114, HQP1351 (Olverembatinib), and K0706 (Vodobatinib), which function 
competitively as inhibitors of BCR-ABL1 TK at the ATP-binding site (Table 2) [249]. These 
inhibitors have presented an increased potency against a wide range of BCR-ABL1 muta-
tions [249–252] and may overcome some the limitations of approved TKIs. Unlike other 
TKIs, Olverembatinib is able to bind to the kinase in the presence of T315I mutations since 
it does not form the hydrogen bond with the hydroxyl group at this residue [251]. On the 
contrary, PF-114 is structurally very similar to Ponatinib but modified to avoid the VEGFR 
inhibition associated with cardiovascular side effects [252]. 
4.2. Non-BCR-ABL1 Targeted Therapies 
Despite the considerable success of BCR-ABL1 inhibitors in CML, even with second 
and third-generation TKI in the clinical setting, this therapeutic protocol is not a curative 
approach. The increased knowledge of CML biology, especially with recognition of 
dormant LSCs, highlights the necessity to explore non-BCR-ABL1 targets [199,253]. Over 
the years, multiple new agents, and "old" drugs with a new purpose (drug-repurposing) 
have been studied in monotherapy or in association with TKIs, to promote a synergistic 
effect, trying to induce CML cell death. 
As mentioned before, a critical protein in the transduction of BCR-ABL1 oncogenic 
signal is GRB2, which is able to activate RAS/MAPK, JAK/STAT, and other signaling path-
ways resulting in cell proliferation stimuli [254]. BP1001 is a liposome incorporated GRB2 
antisense oligonucleotide developed to inhibit GRB2 expression. This agent was under 
phase I clinical trial in CML and other hematological cancers (NCT01159028), and in phase 
II study in combination with Dasatinib (NCT02923986) [255]. Despite the promising re-
sults in preclinical studies and being well tolerated in patients, the BP1001 effect in com-
bination with Dasatinib was insufficient, and the phase II trial was withdrawn. However, 
this approach is currently under investigation in AML and solid tumors [256]. 
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The RAS/MEK/ERK pathway can be activated independently of fusion oncoprotein 
in response to growth factors [257]. An initial step in RAS activation is the transfer of a 
farnesyl group mediated by farnesyltransferase [258]. Tipifarnib (NCT00004009) and Lo-
nafarnib (NCT00047502), two farnesyltransferase inhibitors, were tested in CML resistant 
patients in monotherapy and in combination with Imatinib [259–261]. Although some pos-
itive results have been observed, the clinical interest in these inhibitors for CML treatment 
was ceased. Currently, Lonafarnib is approved for progeria and other conditions [262]. 
Other agents that modulate the RAS/MEK pathway were also explored as potential CML 
therapeutic options. These drugs include Selumetinib (NCT03326310) and Trametinib, 
both MEK inhibitors, and Enzastaurin—a PKC inhibitor [263,264]. 
Ruxolitinib, a JAK2 inhibitor currently approved for myelofibrosis and polycythemia 
vera, demonstrated promising results in combination with TKI in reducing LSC viability 
in CML [265]. Its mechanism of action is associated with direct inhibition of JAK signaling 
but is also linked with enhancing MHC molecules expression making CML cells more 
visible to the immune system [210]. The combination approach of Ruxolitinib with TKI is 
currently under investigation in different clinical trials (NCT03610971, NCT01702064). 
The recognition of the PI3K/AKT/mTOR pathway as an important drug target in on-
cology led to the approval of PI3K inhibitors (as Idelalisib) and mTOR inhibitors (as an 
example of Sirolimus) for different neoplasias [266]. In preclinical studies, Everolimus, an 
mTOR inhibitor, show promising results overcoming TKI resistance in cell lines and ex 
vivo samples [267,268]. Based on these results, Sirolimus (NCT00776373) and Everolimus 
(NCT00081874 and NCT01188889) were evaluated in phase I and II clinical trials in CML 
patients [269]. However, the trials were terminated and completed, respectively, without 
published results and an evaluation of the obtained outcomes. Other agents targeting this 
signaling axis have been explored in preclinical studies, namely Pictilisib (PI3K inhibitor) 
and MK-2206 (AKT inhibitor) [124,270]. 
BCL-2 family members became druggable targets in hematopoietic cancers to over-
come the anti-apoptotic signal in tumor cells [271]. Venetoclax, a specific BCL-2 inhibitor, 
demonstrated in preclinical tests an increase in the apoptotic rate in CML cells and pre-
sented a synergistic effect with TKI against CD34-positive CML cells [272,273]. Approved 
for CLL treatment, Venetoclax is currently in a phase II trial in resistant CML patients in 
combination with Dasatinib (NCT02689440) and in another two trials using a triple com-
bination with Ponatinib and Decitabine (NCT04188405) or Ponatinib and corticosteroids 
(NCT03576547). 
In cancer cells, the repression of tumor suppressor proteins, like P53, leads to uncon-
trolled proliferation, resistance to apoptosis, and survival. The degradation of P53 is me-
diated by MDM2, an E3 ligase that targets the protein to the proteasome. Inhibition of 
MDM2 may constitute a critical approach to restore P53 function and control tumor cell 
fate indirectly [274]. Different MDM2 inhibitors showed satisfactory effects in vitro, and 
AMG-232 (KRT-232) is currently in clinical trials associated with Dasatinib and Nilotinib 
in CML patients (NCT04835584) [275]. Another way to overcome TKI resistance is by the 
inhibition of protein translation [276]. In 2012, the FDA approved the use of Omacetaxine, 
a protein translation inhibitor, to treat resistant CML patients that do not benefit from TKI 
therapy [277]. By inhibiting the synthesis of oncoproteins as BCR-ABL1, Omacetaxine pre-
sented anti-tumor activity against CML cells and showed meaningful response rates in 
clinical trials, even in the case of T315I mutation [278,279]. 
Targeting signaling pathways essential to maintain and regulate key features of LSCs 
is a very promising strategy in different cancers [210]. Inhibition of sonic hedgehog path-
way with Vismodegib (GDC-0449) or Sonidigib (LDE225) in preclinical studies showed a 
reduction in number and self-renewal capacity of CML-LSCs and a possible synergistic 
effect with TKI [280,281]. Although the trial results are not posted yet, Sonidigib was in-
vestigated in combination with Nilotinib in CML patients resistant to prior treatments 
(NCT01456676). Additionally associated with quiescent LSC state and its insensitivity to 
TKI, Pioglitazone may gain a new therapeutic purpose [282]. Used as an antidiabetic drug 
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in type 2 diabetes patients, Pioglitazone is a peroxisome proliferator-activated receptor 
gamma (PPAR-γ) agonist. Several clinical trials are testing this drug in combination with 
TKIs (NCT02889003, NCT02687425) or other drugs (NCT02767063). The rationale behind 
this combination with TKI is based on the capability of Pioglitazone to induce CML LSC 
to exist their quiescent state and become sensitive to TKI therapy [282]. Mechanistically, 
this PPAR-γ agonist downregulates STAT5 and consequently HIF2α and CITED2, crucial 
regulators of the quiescence and stemness state of CML LSC cells [283]. In combination 
with TKI, Pioglitazone is in clinical trials to evaluate its importance not only in resistance 
but also in improving TKI discontinuation and TFR rates. 
Many other molecules and pathway inhibitors were or are currently in preclinical 
studies trying to overcome resistance and may constitute future therapeutic options in 
CML. The exploitation of other signaling pathways either alone or in combination with 
BCR-ABL1 drugs will, sooner or later, become a reality in CML treatment to improve re-
sponse, avoid resistance, and enhance treatment discontinuation probability. 
4.3. Epigenetic Modulators 
The fact that epigenetic modifications can be manipulated pharmacologically has led 
to their successful use in clinical practice in both myeloid and lymphoid malignancies. 
The two most commonly used DNA hypomethylating agents are Azacitidine and 
Decitabine and both have been particularly successful in the treatment of MDS [284–286] 
and AML [287,288]. Decitabine has been tested as both first and second line in CML pa-
tients. One hundred and thirty naïve CML patients were treated with escalating doses of 
Decitabine, having achieved hematological responses in a significant number but at the 
cost of prolonged myelosuppression [289]. Lower doses of Decitabine were tested in a 
phase 1 trial of treatment naïve CML patients with better hematological and cytogenetic 
responses [290]. In Imatinib-resistant CML patients, Decitabine was tested in combination 
with higher doses of Imatinib, achieving hematologic responses in 30–50% patients [291]. 
Unfortunately, none of these combinations demonstrated sufficient efficacy to justify their 
clinical use. 
Histone modifications can also be manipulated pharmacologically, especially with 
HDAC inhibitors. These include aliphatic acids (phenylbutyrate), cyclic peptides (ro-
midepsin), benzamides (entinostat), electrophilic ketones, and hydroxamates (vorinostat) 
and may restore normal acetylation of histone proteins and transcription factors [292]. 
Some HDAC inhibitors have been successful in treating hematological malignancies, such 
as vorinostat for cutaneous T-cell lymphomas [293]. There is also in vitro evidence that 
vorinostat has a significant effect in chronic myeloid malignancies [294] and may act syn-
ergistically with TKI to induce p21 and p27 expression and inhibit BCR-ABL1 levels 
[295,296]. However, there are no firm clinical data to corroborate these laboratory find-
ings, for the use of these agents in CML. 
4.4. Immunotherapies 
During the past decade, considerable progress has been made in the immunology 
understanding of CML, raising hopes that this disease may be curable by improving the 
currently targeted chemotherapy with immunotherapeutic approaches [297]. Immune re-
sponses against CML-specific and CML-associated antigens such as BCR-ABL1, protein-
ase-3, and WT-1 can be detected in CML patients, suggesting it sensitivity to immune con-
trol. Besides that, donor lymphocyte infusions can induce long-lasting remissions in re-
lapsed CML patients after allogeneic stem cell transplant (SCT) [247]. Through the use of 
T cell-based immunotherapy, CML-specific immune responses may be strengthened, ex-
tending the fraction of patients achieving long-term TFR or even complete cure. It has 
been shown that "non-specific" immunotherapy approaches, such as allogeneic stem cell 
transplantation or interferon-α (IFN-α) therapy, enable long-lasting remissions in CML 
patients after discontinuation of TKI therapy [298]. The anti-leukemic effect of IFN-α is 
through a direct anti-proliferative effect, specifically on CML progenitor cells, but it also 
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has an immunomodulating action. In clinical practice, in the TKI era, interferon in mono-
therapy has a limited place and is mainly used for patients who were TKI intolerant or 
that could not be treated with a TKI (for example during pregnancy) [247]. With the ad-
vent of pegylated formulations, having higher tolerability, interferon has re-emerged as 
an attractive therapeutic option in CML [2]. Besides that, and because of their different 
modes of action, exploration of the potential to combine interferon with TKI therapy is 
also a possibility, being the pegylated form of interferon in combination with the second-
generation TKIs, Nilotinib and Dasatinib (NCT01866553, NCT01872442), and with Bosu-
tinib (NCT03831776) [212,247,249]. 
Several cooperative groups and trials showed significantly higher complete cytoge-
netic remissions and major molecular remission rates for patients treated with Imatinib in 
combination with IFN-α as compared with patients treated with Imatinib alone (Italian 
GIMEMA, Nordic CML study group French SPIRIT trial, German CML IV trial). How-
ever, the interferon discontinuation rate in all studies was high (83%), mainly due to tox-
icity. None of those studies mentioned above found a statistically significant reduction in 
progression to advanced disease phase or prevention of CML-related death [247]. 
In CML patients, particularly in those classified as high risk by the Sokal score, the 
expression of the immune checkpoint proteins PD-L1 and PD-1 had been observed. Thus, 
the upregulation of PD-L1 is considered an immunological escape mechanism for CML 
cells [247,249]. These data suggest that targeting the PD-1/PD-L1 pathway may be an ef-
fective strategy for eliminating CML cells [249], and treatment with ICIs could potentially 
increase immunoreactivity against leukemic cells in CML [4]. Several clinical trials have 
evaluated the combination of ICIs with TKI therapies (NCT02011945, NCT02767063, 
NCT03516279, NCT01822509) [204]. Monoclonal antibodies, such as Pembrolizumab, may 
interfere with the ability of cancer cells to grow and spread. Administrating Pembroli-
zumab in combination with TKIs may be more effective in treating patients with CML. A 
clinical trial (NCT01822509) is currently evaluating the efficacy of Ipilimumab (anti-CTLA-
4) in combination with Nivolumab (anti-PD1) in patients with hematological malignancies, 
including CML [204]. Although the mechanism of action of the ICIs in CML is unclear, it 
has been demonstrated, in murine models, that the therapeutic effects of PD1/PDL1 block-
ade may be mediated, at least in part, through a strong NK response [204]. 
More advanced therapeutic strategies, e.g., vaccines or engineered T cells, are in 
study to treat CML patients aiming to induce an immune response against the leukemic 
cells. In general, tumor-associated HLA-presented peptides on malignant cells are rele-
vant targets. However, the role of these neoantigens in cancers with a low mutational bur-
den, such as CML, remains unclear. Several small studies have investigated the potential 
to induce an anti-leukemic vaccination response in CML patients. One strategy uses ex-vivo 
generated autologous dendritic cells and other leukemia-associated antigens as the injection 
of BCR-ABL1 derived peptides (NCT02543749). This strategy has shown clinical efficacy by 
inducing a T-cell response in most patients and was safe and feasible. However, these stud-
ies are single arm and, therefore, prospective randomized trials are needed [247]. 
Chimeric antigen receptor (CAR)-T cells are an emerging immunotherapy already 
approved for B-cell malignancies and are being evaluated for myeloid malignancies. The 
IL1 receptor accessory protein (IL1RAP), a co-receptor for the IL1 and IL33 receptors, is a 
cell-surface marker expressed by CML cells but not by normal HSCs. In vitro and in vivo 
studies suggest that CART-cells targeting IL1RAP specifically induce cell death of quies-
cent CML stem cells and have a favorable side effect profile without off-target toxicity or 
tumor lysis syndrome, some of the adverse events more commonly associated with CAR-
T therapy. A combined CAR-T and TKI approach has also been used to eliminate CML 
stem cells in limited clinical series. An anti-CD19 CAR-T therapy combined with Dasatinib 
induced complete molecular remission and the return to CP in CML patients in lymphoid 
BC harboring T315I mutation. This CART cleared the T315I mutation and re-sensitized 
cells to Dasatinib. The same effect was observed against RUNX1 mutations in BC-CML 
patient, where the anti-CD19 CAR-T showed an additive effect when combined with 
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Imatinib. These studies suggest that CART-cells may confer therapeutic benefit, particu-
larly in young or advanced-phase CML patients who are resistant/intolerant to TKI, high-
lighting the critical importance of the immune system in optimizing treatment responses 
in CML [204]. 
4.5. Allogenic Stem Cell Transplantation 
In TKI pre-era allogenic stem cell transplantation (Allo-SCT) represented a therapeu-
tic option for patients at CP-CML with a compatible donor and fit for the procedure [299]. 
However, currently this option has a more important role for patients that evolve into 
AP/BP-CML and remains an important therapeutic option for CP-CML patients that pre-
sented resistance to second line TKI or first line TKI resistance with T315I mutations, in 
agreement with ELN guidelines [212]. According to expert opinions, in case of second line 
TKI resistance the search for a compatible donor should be initiated as early as possible. 
This is justified by the time taken until find an unrelated donor, since two thirds of pa-
tients do not have a matched-related donor [300]. 
The appropriated time for perform Allo-SCT has not established yet, and the decision 
must be based on patient’s individual benefit–risk assessment. The multiple transplant-
associated risks, such as non-relapse mortality and graft versus host disease, and the pres-
ence of high-risk ACA are some of the factors to be considered in patient evaluation [299]. 
In case of young patients, the transplant should be preferred to a third line TKI, such as 
Ponatinib, if a donor is available [300]. This therapeutic approach is an effective alternative 
for TKI-resistant or intolerant patients. However the strategies to adopt after Allo-SCT to 
avoid relapse continue to be poorly elucidated [301,302]. 
5. Patient's Adhesion Impact on Resistant Process 
In CML treatment, the introduction of TKIs had been considered a revolutionary and 
successful therapeutic, leading to a normal life expectancy. However, a substantial pro-
portion of CML patients fail treatment with drug interruption and discontinuation, rap-
idly leading to disease resurgence due to minimal residual disease re-emergence [303] and 
probably contributing to drug resistance development. 
In this context, adherence to therapy and compliance with clinical instructions are 
critical in the management of CML. Adherence to long-term therapy is defined by the 
World Health Organization (WHO) as "the extent to which patients' behavior taking med-
ication corresponds with agreed recommendations from a healthcare provider” [304]. The 
adherence rates to oral anticancer therapies vary greatly, ranging between 0% and 83%, 
with an average non-adherence rate estimated at 21%. These variations can be partly ex-
plained by differences in measurements and definitions of non-adherence [16]. There are 
diverse methods previously described to verify adherence being the most common the 
medication possession ratio (MPR), the continuous measure of adherence (CMA), and the 
proportion of days covered (PDC) [17]. 
Several studies have shown that lack of adherence to Imatinib is frequent and may 
significantly impact patient outcomes. A Belgian study found that only 14% of CML pa-
tients took all of their prescribed Imatinib. This lack of compliance led to increased subop-
timal responses [305]. Others show that 26% of the patients on long-term Imatinib therapy 
have an adherence rate lower than 90% being this the most important factor determining 
the achievement of molecular responses [306]. In addition, a study in the US found that 
31% of 267 CML patients were identified as having treatment interruptions of Imatinib at 
least 30 consecutive days during a year follow-up period and that this non-adherence in-
creased health care costs [307]. A study performed in Qatar showed a high rate of treat-
ment failure explained by poor adherence, economic factors being the main causes of non-
adherence [303]. In vitro models exposed to discontinuous TKI, which mimics the conse-
quence of poor adherence or other causes of treatment interruptions, emphasizes the com-
plexity of the Imatinib resistance process [87]. As described, the low adherence to Imatinib 
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is a common problem in clinical practice being a significant risk of therapeutic failure and 
Imatinib resistance as well as for increased health care services costs [17]. 
The factors that seem to facilitate adherence are fitting the Imatinib into the daily 
routine, using prompts to remember to take the tablets and finding ways of coping with 
side effects. Another intervention that may help reduce intentional non-adherence is mak-
ing a patient phone call and discussing how they are getting on with their medication. The 
interventions to improve adherence need to consider both intentional and unintentional 
reasons for not taking Imatinib and should target the specific personal reasons for not 
correctly receiving TKI treatment [16]. 
6. Conclusions 
Chronic myeloid leukemia was a pioneer in terms of targeted treatment approaches 
[308]. The development of tyrosine kinase inhibitors able to counteract the function of 
BCR-ABL1 oncoprotein improved the survival of CML patients substantially [308,309], 
changing the natural course of this disease [309,310]. Despite the spectacular progress 
made over the last two decades to obtain new TKIs that target CML, multiple patients still 
develop resistance to these drugs. 
The molecular mechanisms behind TKI resistance are multiple, ranging from changes 
in the molecular drug target itself, to mechanisms that alter drug concentration or modify 
leukemic cells signaling network [23]. In addition, the modifications on tumor microenvi-
ronment and immune cell dysfunction may compromise drug response(s). Alterations in 
drug target are the most common mechanism of resistance in CML, but are not exclusive. 
Exploiting BCR-ABL1 independent mechanisms seems to be important to understand and 
identify the role of other proteins in treatment response [27]. Identification of biomarkers 
of drug response are crucial for a better treatment selection and some of them may consti-
tute new targets for future therapeutic approaches [180]. Additionally, inherent genetic 
variants, such as SNVs, may modulate or affect the predisposition to disease, prognosis, 
and drug response [311]. 
In this context, blood stem cell transplant therapy is the only proven cure for these 
patients, but this therapy has higher toxicity and is limited by donor availability [212,312]. 
This fact highlights the need for the development of new therapeutic approaches against 
resistance for CML treatment. The point mutations in BCR-ABL1 chimeric protein, includ-
ing the gatekeeper T315I mutation, are the principal cause for the development of re-
sistance to TKIs. However, other mechanisms are also involved in the failure of TKI ther-
apy [312]. Considering these causes of therapy failure, several strategies have been used 
to overcome drug resistance in CML: (I) the use of drugs targeting the allosteric site of 
BCR-ABL1 oncoprotein; (II) the use of drugs targeting the ATP site of BCR-ABL1 along 
with drugs that bind in a different way to Imatinib; (III) the use of drugs, like Asciminib, 
that target the myristoyl pocket of BCR-ABL1; (IV) the combined use of several TKIs; (V) 
the use of a TKI in combination with other drugs that target different objectives, such as 
TKI+IFN-α, TKI+chemotherapy, TKI+immune-modulators, etc. [210]; (vi) the use of new 
TKIs designed to overcome ABL1 gatekeeper mutations (mainly T315I) that at present are 
only preclinically validated [248]. All these therapeutic approaches are taken in second 
and third line treatments when initial therapies are not efficient or faint over time due to 
the emergence of resistance. 
The emerging landscape of immune dysfunction and immunosurveillance in CML 
highlights the critical importance of the immune system in optimizing treatment re-
sponses in CML. Curiously, IFN-α, a previous standard of care therapy, exhibits non-spe-
cific, untargeted effects on the immune system, leading to repurpose it in order to enhance 
TFR in the TKI era. However, newer precision oncology approaches targeting immune 
system, such as vaccines, ICIs, and CAR-T-cell therapies constitute a great promise in 
CML therapy, especially in cases of TKI resistance and/or intolerance. Together, specific 
and non-specific immunological effectors can make the concept of "operational cure" a 
reality for the vast majority of patients in the next decade [204]. 
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